DOXORUBICINE ARROW 2 mg/ml

DRUG2 trials

Sponsors

Unicancer, Institut Curie

Conditions

Breast cancerFIGO stage I (2018 classification)Localizedresecteduterine leiomyosarcoma

Phase 1

"FAP-IT" 68Ga-FAPI-46 PET/CT for predicting histological response to neoadjuvant chemo-immunotherapy in triple-negative breast cancer

RecruitingCTIS2023-507860-37-00

Institut CurieBreast cancer

Start: 2024-10-14Target: 300Updated: 2025-11-10

Phase 2

L-UteCIN : Interest of adjuvant chemotherapy in patients with CINSARC high-risk localized resected uterine leiomyosarcoma

RecruitingCTIS2023-506350-21-00

UnicancerFIGO stage I (2018 classification), Localized, resected +1

Start: 2025-01-06Target: 198Updated: 2025-03-25